Table 5.
POMS2 scores for DHA/EPA and placebo treatment groups.
| Variable | Baseline | Week 12 | ||||
|---|---|---|---|---|---|---|
| DHA/EPA Group (n = 33) | Placebo Group (n = 33) | p Value | DHA/EPA Group (n = 33) | Placebo Group (n = 33) | p Value | |
| Anger–hostility | 46.8 ± 9.0 | 48.1 ± 12.3 | 0.955 | 47.1 ± 10.4 | 46.9 ± 8.5 | 0.996 |
| Confusion–bewilderment | 47.1 ± 8.9 | 47.4 ± 8.7 | 0.633 | 47.0 ± 9.4 | 47.5 ± 7.6 | 0.481 |
| Depression–dejection | 49.3 ± 9.5 | 48.3 ± 8.1 | 0.889 | 48.8 ± 8.4 | 48.0 ± 6.2 | 0.832 |
| Fatigue–inertia | 47.9 ± 8.4 | 46.7 ± 7.4 | 0.656 | 46.2 ± 9.2 | 46.3 ± 7.7 | 0.856 |
| Tension–anxiety | 50.4 ± 9.0 | 48.3 ± 9.0 | 0.537 | 48.7 ± 9.1 | 48.8 ± 8.5 | 0.677 |
| Vigor–activity | 52.8 ± 10.7 | 50.9 ± 9.7 | 0.356 | 54.4 ± 10.5 | 54.5 ± 9.6 | 0.332 |
| Friendliness | 53.0 ± 11.2 | 52.7 ± 10.0 | 0.458 | 53.9 ± 10.9 | 53.3 ± 9.7 | 0.414 |
| Total mood disturbance | 47.7 ± 8.6 | 47.6 ± 8.9 | 0.908 | 46.8 ± 9.2 | 46.7 ± 6.9 | 0.853 |